Lates News

Novo Nordisk: Novo Nordisk's real-world study shows that in adult patients with metabolic dysfunction-associated steatohepatitis, the use of Wegovy at a 2.4 mg dose is associated with reductions in liver enzymes, body weight, and blood glucose.